Ultragenyx to Present at the Stifel Nicolaus Weisel Healthcare Conference 2012 in Boston

Ultragenyx to Present at the Canaccord Genuity 32nd Annual Growth Conference on August 16, 2012

Ultragenyx to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference on August 15

Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy, a Rare Neuromuscular Disease

Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease

Ultragenyx Relocates Company Headquarters to Support Operational Expansion

Ultragenyx Appoints Shalini Sharp as Chief Financial Officer and Senior Vice President, Finance

Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7

Ultragenyx Announces the Completion of the Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease

Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)